Allergan plc (NYSE: AGN) topped market forecasts on revenue and earnings for the first quarter of 2019. Despite the beat, shares fell 0.5% in premarket hours on Tuesday.
Total revenue decreased 2% year-over-year to $3.60 billion. The company’s core business grew 4.4% year-over-year across its four key therapeutic areas, helped by growth of products such as BOTOX Cosmetic, BOTOX Therapeutic, VRAYLAR, JUVEDERM and Lo LOESTRIN.
GAAP net loss attributable to ordinary shareholders was $2.4 billion, or $7.25 per share, versus $332.5 million, or $0.99 per share, in the year-ago period. Adjusted EPS grew 1.3% to $3.79.
In US Specialized Therapeutics, revenues decreased 2.3% year-over-year to $1.54 billion due to lower revenues in CoolSculpting and RESTASIS as well as the divestiture of the Medical Dermatology business, which offset the demand growth in BOTOX and JUVEDERM.
US General Medicine revenues grew 2.1% to $1.25 billion, primarily due to growth in VRAYLAR and Lo LOESTRIN. International revenues grew 1.3% to $801.5 million, due to growth in Facial Aesthetics.
Also see: Allergan Q1 2019 Earnings Conference Call Transcript
Allergan raised its outlook for the full year of 2019, and now expects GAAP net revenues to be in the range of $15.12 billion to $15.42 billion. Adjusted revenues are expected to be $15.10 billion to $15.40 billion. GAAP loss is expected to be $5.70 per share while adjusted EPS is expected to be $16.55.
For the second quarter of 2019, GAAP revenues are expected to be $3.87 billion to $4.02 billion. Adjusted revenues are expected to be $3.85 billion to $4.00 billion. GAAP EPS is expected to come in the range of $0.50-0.70 while adjusted EPS is expected to be $4.20-4.40.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Important takeaways from Paychex’s (PAYX) Q2 2025 earnings report
Paychex Inc. (NASDAQ: PAYX), a leading provider of human resources and payroll services, reported better-than-expected revenue and profit for the second quarter of fiscal 2025, sending the stock higher soon
Lamb Weston’s (LW) challenges may not end soon, a few points to note
Shares of Lamb Weston Holdings, Inc. (NYSE: LW) turned red in mid-day trade on Friday. The stock has dropped 19% in the past one month. The company delivered disappointing results
CCL Earnings: Carnival Corp. Q4 2024 revenue rises 10%
Carnival Corporation & plc. (NYSE: CCL) Friday reported strong revenue growth for the fourth quarter of 2024. The cruise line operator reported a profit for Q4, compared to a loss